Coronavirus Update: RECOVERY Finds Kaletra Ineffective, Indian Company Joins Vaccine Race

Plus: Could Tweaks Boost Remdesivir Benefits?

A third set of authoritative results from UK trial ruled out use of AbbVie's HIV combination, plus Bharat Biotech to launch Phase I vaccine trials.  

Please Wait Here
Phoenix, Arizona, June 2020: The US state's governor has just rolled back reopening of bars and gyms and other businesses after a rapid rise in COVID-19 cases.

A large randomized trial of AbbVie Inc.’s Kaletra (lopinavir-ritonavir) has been found to have no benefits for patients hospitalized with COVID-19, despite early hopes for the HIV combination therapy.

The result are the third major finding of the adaptive RECOVERY trial led by the University of Oxford in the...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from COVID-19

More from Scrip